Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immunotherapy Overtaking Breast Cancer Treatment Landscape

Publish date:: June 13, 2019

Key clinical point: Combination strategies that include immunotherapeutic agents could soon become the future of breast cancer treatment.

Major finding: Immune checkpoint blockade agents are the most studied type of immunotherapy in breast cancer today.

Study details: A narrative review summarizing current immunotherapeutic agents in the treatment of breast cancer.

Disclosures: No funding sources were reported. The authors reported financial affiliations with Amgen, Celgene, Genentech, Eli Lilly, Ipsen, Novartis, Pfizer, and several others.

Citation:

Adams S et al. JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,